1-4 of 4
Alain Leizorovicz, MD
Close
Sort by
Journal Articles

Fondaparinux Reduces All Types of Symptomatic Thromboembolic Complications in Patients with Superficial-Vein Thrombosis in the Legs: Data From the CALISTO Study

Alain Leizorovicz, MD, Paolo Prandoni, Hervé Décousus, MD
Journal: Blood
Blood (2011) 118 (21): 2310.
https://doi.org/10.1182/blood.V118.21.2310.2310
Published: 2011
Journal Articles

Fondaparinux 2.5mg for the Treatment of Symptomatic, Isolated Superficial Vein Thrombosis (SVT): Preliminary Data From the Randomized Placebo-Controlled CALISTO Trial (on Behalf of the CALISTO Investigators).

Hervé Décousus, MD, Paolo Prandoni, MD, Alain Leizorovicz, MD
Journal: Blood
Blood (2009) 114 (22): 171.
https://doi.org/10.1182/blood.V114.22.171.171
Published: 2009
Journal Articles

No Accumulation of Peak Anti-Xa Activity of Tinzaparin in Elderly Patients with Moderate to Severe Renal Impairment: A Substudy of IRIS Clinical Trial.

Virginie Siguret, Alain Leizorovicz, MD, Eric Pautas, Isabelle Gouin-Thibault
Journal: Blood
Blood (2009) 114 (22): 172.
https://doi.org/10.1182/blood.V114.22.172.172
Published: 2009
Journal Articles

Tinzaparin Compared to Unfractionated Heparin for Initial Treatment of Deep Vein Thrombosis in Very Elderly Patients with Renal Insufficiency-the IRIS Trial

Alain Leizorovicz, MD
Journal: Blood
Blood (2008) 112 (11): 434.
https://doi.org/10.1182/blood.V112.11.434.434
Published: 2008